VIVEbiotech at ASGCT 2026: Science and Collaboration
The company strengthens its position in gene and cell therapy with lentiviral manufacturing insights
VIVEbiotech is participating in the ASGCT Annual Meeting 2026, taking place this week in Boston, one of the leading global events in the field of gene and cell therapy. The congress brings together scientists, biotech companies, and industry experts to share the latest advances and foster collaboration across the sector.
Throughout the event, VIVEbiotech will welcome attendees at booth 1619, where its team will present the company’s capabilities in the development and manufacturing of lentiviral vectors for both ex vivo and in vivo applications. The VIVEbiotech representatives on site include Marina Pellon Consunji (Board Member), Natalia Elizalde, PhD (Chief Business Development Officer), Marie Fertin (Chief Custom Solution & Process Development Officer), and Víctor Polo (Business Development Manager).
In addition to its exhibition presence, VIVEbiotech will contribute to the scientific program with two sessions scheduled for May 12. The first is a company presentation at 4:00 PM, titled “Shaping the Future of Lentiviral Vector Manufacturing: Versatile Platforms for Ex Vivo and In Vivo Applications”, where the company will highlight its flexible manufacturing platforms designed to support diverse therapeutic approaches.
On the same day, VIVEbiotech will also participate in a symposium sponsored by Sartorius at 4:30 PM, entitled “A Collaborative Approach to Enabling Efficient LV Manufacturing for Ex Vivo and In Vivo Gene Therapies”. This session will emphasize the importance of collaboration in advancing efficient and scalable manufacturing processes for advanced therapies.
VIVEbiotech would like to acknowledge Sartorius–Advanced Therapy Solutions and Sartorius–Bioprocess Solutions for their invitation and collaboration in this scientific initiative.
During the event, the VIVEbiotech team is available for meetings via the EventPilot app, encouraging networking and discussions around potential partnerships across the full development lifecycle, from early-stage discovery to commercial-scale manufacturing.
For those not attending ASGCT this year, VIVEbiotech remains available to connect and explore collaboration opportunities in lentiviral vector solutions.